Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority,phase 3 TURANDOT trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F13%3A33145197" target="_blank" >RIV/61989592:15110/13:33145197 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/S1470-2045(12)70566-1" target="_blank" >http://dx.doi.org/10.1016/S1470-2045(12)70566-1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S1470-2045(12)70566-1" target="_blank" >10.1016/S1470-2045(12)70566-1</a>
Alternative languages
Result language
angličtina
Original language name
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority,phase 3 TURANDOT trial
Original language description
Background Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine significantly improves progression-free survival and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated. We compared the efficacy of the two regimens.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Lancet Oncology
ISSN
1470-2045
e-ISSN
—
Volume of the periodical
14
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
125-133
UT code for WoS article
—
EID of the result in the Scopus database
—